Dr. David G. Steiner, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Rush Medical College of Rush University (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 262
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Rush Medical College of Rush University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 199190-2
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Five Towns Neurology, PC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 262
- Services billed
- 2,912
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Therapy procedure using manual technique, each 15 minutes | 683 | 37 |
| Established patient office or other outpatient visit, 40-54 minutes | 242 | 116 |
| Established patient office or other outpatient visit, 30-39 minutes | 179 | 79 |
| Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | 131 | 24 |
| Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 89 | 20 |
| Measurement of brain wave activity (eeg), digital analysis | 85 | 68 |
| Ultrasound of both sides of head and neck blood flow | 85 | 85 |
| Measurement of brain wave activity (eeg), awake and drowsy | 75 | 73 |
| New patient office or other outpatient visit, 45-59 minutes | 73 | 73 |
| Mri scan of brain without contrast | 66 | 66 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tizanidine Hcl Other prescribers in Woodmere, NY | 198 |
| Nabumetone Other prescribers in Woodmere, NY | 131 |
| Gabapentin Other prescribers in Woodmere, NY | 108 |
| Donepezil Hcl Other prescribers in Woodmere, NY | 106 |
| Budesonide Er (budesonide) Other prescribers in Woodmere, NY | 93 |
| Topiramate Other prescribers in Woodmere, NY | 80 |
| Meloxicam Other prescribers in Woodmere, NY | 50 |
| Duloxetine Hcl Other prescribers in Woodmere, NY | 50 |
| Levetiracetam Other prescribers in Woodmere, NY | 44 |
| Dalfampridine Er (dalfampridine) | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 33 companies reported 157 payments worth $4,121 in total to this clinician.
| Mallinckrodt Hospital Products Inc. | $604 |
|---|---|
| Harmony Biosciences LLC | $561 |
| AbbVie Inc. | $321 |
| Axsome Therapeutics, Inc. | $259 |
| Tg Therapeutics, Inc. | $222 |
| Argenx US, Inc. | $209 |
| Biogen, Inc. | $200 |
| Celgene Corporation | $188 |
| Food and Beverage | $4,051 |
|---|---|
| Education | $69.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Harmony Biosciences LLC Jun 11, 2025 | Education in-kind | $69.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $62,608 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05511363 - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.